Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.
P/E ratio for Intercept Pharmaceuticals, Inc. (ICPT)
P/E ratio as of 2022: 3.63
According to Intercept Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 3.63. At the end of 2021 the company had a P/E ratio of -3.58.
P/E ratio history for Intercept Pharmaceuticals, Inc. from 2010 to 2022
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2022 | 3.63 |
| 2021 | -3.58 |
| 2020 | -2.51 |
| 2019 | -10.03 |
| 2018 | -9.28 |
| 2017 | -4.06 |
| 2016 | -6.49 |
| 2015 | -15.63 |
| 2014 | -11.45 |
| 2013 | -18.16 |
| 2012 | -4.93 |
| 2011 | -5.07 |
| 2010 | -4.28 |